157 related articles for article (PubMed ID: 20528413)
1. The cost-effectiveness of rituximab in non-Hodgkin's lymphoma.
Knight C; Maciver F
Expert Rev Pharmacoecon Outcomes Res; 2007 Aug; 7(4):319-26. PubMed ID: 20528413
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
6. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
8. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.
Keating GM
BioDrugs; 2011 Feb; 25(1):55-61. PubMed ID: 21222497
[TBL] [Abstract][Full Text] [Related]
10. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
[TBL] [Abstract][Full Text] [Related]
12. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
16. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
18. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
19. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
